BTC Health (ASX: BTC), under its subsidiary BTC Cardio, has obtained exclusive distribution privileges for the ExoVasc® Personalised External Aortic Root Support (PEARS) from UK-based Exstent Limited. This innovative medical device, designed for individuals with Marfan syndrome and similar conditions, aids in managing aortic dilation by reinforcing the ascending aorta, thereby preventing its enlargement and rupture.
With over 1,000 patients treated and a history of success spanning nearly two decades, the ExoVasc represents a significant advancement in treating dilated aortas. Following an agreement with Advanced Biomedical, which had been distributing ExoVasc in Australia since 2018, BTC Cardio will now spearhead the device's distribution, aiming for a $700K revenue in its first year with expectations of a 10-15% annual growth. This move underscores BTC's commitment to enhancing cardiothoracic care and offers a new, life-changing surgical option for patients.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
